Plasma Cell Leukemia
Plasma cell leukemia (PCL) is a rare and aggressive blood cancer characterized by an abnormal increase of plasma cells in the blood and bone marrow, leading to various health complications.
Primary Plasma Cell Leukemia: New Treatment with Bortezomib and Daratumumab
We are studying a combination of medications for people with primary plasma cell leukemia to see if it improves treatment outcomes and safety. This trial will help us understand how well this new approach works compared to current treatments.
What diseases are being studied?
Health conditions and diseases that the clinical trial is designed to study and treat.
Who can participate in the clinical trial?
These questions help us understand your situation so we can let the trial team know whether you might be a potential match. This is not a medical evaluation and is not part of the official screening, the study doctor will make the final decision..
- Are you between 18 and 80 years old?
- Do you have any serious heart problems, like a recent heart attack or unstable angina?
- Are you currently pregnant, breastfeeding, or planning to become pregnant in the next 3 months?
- Are you taking any strong medications that affect liver enzymes, like rifampicin or carbamazepine?
- Have you had major surgery in the last 2 weeks?
What similar medicines might you know?
Don't worry if you don't know the medicines tested in the trial. There is a chance you have heard about the similar medicines. Check the list below to see if you are familiar with any of them.
Abormib
Adabonib
Bortega
Where is the clinical trial being conducted?
Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.
Loading map...
University General Hospital Of Alexandroupoli
Hematology Clinic
Alexandroupoli, Greece
Geniko Nosokomeio Thessalonikis George Papanikolaou
Hematology Clinic
Asvestochóri, Greece
Alexandra Hospital
Department of Clinical Therapeutics
Athens, Greece
Sponsor: Hellenic Society Of Hematology
Last updated: Nov 26, 2025
Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.